Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds

Takeda Pharmaceutical

18/05/2026 19:33

BOSTON, May 18 (Reuters) - A U.S. jury on Monday found that Takeda Pharmaceutical 4502.T caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version of its anti-constipation drug Amitiza through an anticompetitive scheme.

 (Reporting by Nate Raymond in Boston; Editing by Chris Reese)

 ((Nate.Raymond@thomsonreuters.com; 347-243-6917; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net))